<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported May 11, 2000
----------------
BIOLABS, INC. ("BILB")
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
NEW YORK 0-30252 98-0163232
- --------------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction or incorporation) File Number) Identification No.)
1A-3033 KING GEORGE HIGHWAY SURREY, B.C. CANADA V4P 1B8
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 604-542-0820
-----------------
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
<PAGE>
ITEM 5. OTHER EVENTS.
On or about May 11, 2000, the Company was advised that the Phase I/II
Therapeutic Clinical Trials of Mammastatin had been delayed by the FDA to
address production controls. The Company's principal asset is its 50% Joint
Venture interest in an entity developing an MSA test for breast cancer.
The Company was advised by Biotherapies Inc., its Joint Venture partner,
in which it also holds a 12.6% equity interest, that corrective action has
been taken to remedy the incident. The Company has been informed that
Biotherapies has sufficient quantities of Mammastatin to complete the current
phase of clinical trials. The Company does not believe that this
interruption in the clinical trials will materially adversely impact on its
Joint Venture interests in the use of Mammastatin as a diagnostic for cancer
testing. The Company publicly announced the delay in the clinical trials by
news release dated May 11, 2000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BioLabs , Inc. ("BILB")
------------------------
(Registrant)
Date 05/17/00 /s/ Lawrence J. Pasemko
-------- ------------------------
Lawrence J. Pasemko
Chief Financial Officer,
Secretary & Director
